Literature DB >> 19806613

Association study of SNAP25 and schizophrenia in Irish family and case-control samples.

A H Fanous1,2,3, Z Zhao4, E J C G van den Oord3,5, B S Maher3, D L Thiselton3, S E Bergen3, B Wormley3, T Bigdeli3, R L Amdur1,2, F A O'Neill6, D Walsh7, K S Kendler3,8, B P Riley3,8.   

Abstract

SNAP25 occurs on chromosome 20p12.2, which has been linked to schizophrenia in some samples, and recently linked to latent classes of psychotic illness in our sample. SNAP25 is crucial to synaptic functioning, may be involved in axonal growth and dendritic sprouting, and its expression may be decreased in schizophrenia. We genotyped 18 haplotype-tagging SNPs in SNAP25 in a sample of 270 Irish high-density families. Single marker and haplotype analyses were performed in FBAT and PDT. We adjusted for multiple testing by computing q values. Association was followed up in an independent sample of 657 cases and 411 controls. We tested for allelic effects on the clinical phenotype by using the method of sequential addition and 5 factor-derived scores of the OPCRIT. Nine of 18 SNPs had P values <0.05 in either FBAT or PDT for one or more definitions of illness. Several two-marker haplotypes were also associated. Subjects inheriting the risk alleles of the most significantly associated two-marker haplotype were likely to have higher levels of hallucinations and delusions. The most significantly associated marker, rs6039820, was observed to perturb 12 transcription-factor binding sites in in silico analyses. An attempt to replicate association findings in the case-control sample resulted in no SNPs being significantly associated. We observed robust association in both single marker and haplotype-based analyses between SNAP25 and schizophrenia in an Irish family sample. Although we failed to replicate this in an independent sample, this gene should be further tested in other samples. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19806613      PMCID: PMC2859301          DOI: 10.1002/ajmg.b.31037

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  63 in total

Review 1.  Methods of correcting for multiple testing: operating characteristics.

Authors:  B W Brown; K Russell
Journal:  Stat Med       Date:  1997-11-30       Impact factor: 2.373

2.  Increased concentrations of presynaptic proteins in the cingulate cortex of subjects with schizophrenia.

Authors:  S M Gabriel; V Haroutunian; P Powchik; W G Honer; M Davidson; P Davies; K L Davis
Journal:  Arch Gen Psychiatry       Date:  1997-06

3.  Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.

Authors:  B Angrist; J Rotrosen; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

4.  Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics.

Authors:  A D Sherman; T S Hegwood; S Baruah; R Waziri
Journal:  Biol Psychiatry       Date:  1991-12-15       Impact factor: 13.382

5.  Inhibition of axonal growth by SNAP-25 antisense oligonucleotides in vitro and in vivo.

Authors:  A Osen-Sand; M Catsicas; J K Staple; K A Jones; G Ayala; J Knowles; G Grenningloh; S Catsicas
Journal:  Nature       Date:  1993-07-29       Impact factor: 49.962

6.  Altered levels of the synaptosomal associated protein SNAP-25 in schizophrenia.

Authors:  P M Thompson; A C Sower; N I Perrone-Bizzozero
Journal:  Biol Psychiatry       Date:  1998-02-15       Impact factor: 13.382

7.  Diminished synaptosomal dopamine (DA) release and DA autoreceptor supersensitivity in schizophrenia.

Authors:  L Hetey; R Schwitzkowsky; T Ott; H Barz
Journal:  J Neural Transm Gen Sect       Date:  1991

8.  The Roscommon Family Study. I. Methods, diagnosis of probands, and risk of schizophrenia in relatives.

Authors:  K S Kendler; M McGuire; A M Gruenberg; A O'Hare; M Spellman; D Walsh
Journal:  Arch Gen Psychiatry       Date:  1993-07

9.  An international two-stage genome-wide search for schizophrenia susceptibility genes.

Authors:  H W Moises; L Yang; H Kristbjarnarson; C Wiese; W Byerley; F Macciardi; V Arolt; D Blackwood; X Liu; B Sjögren
Journal:  Nat Genet       Date:  1995-11       Impact factor: 38.330

10.  Negative symptoms and hypofrontality in chronic schizophrenia.

Authors:  A Wolkin; M Sanfilipo; A P Wolf; B Angrist; J D Brodie; J Rotrosen
Journal:  Arch Gen Psychiatry       Date:  1992-12
View more
  10 in total

1.  Meta-analysis of Positive and Negative Symptoms Reveals Schizophrenia Modifier Genes.

Authors:  Alexis C Edwards; Tim B Bigdeli; Anna R Docherty; Silviu Bacanu; Donghyung Lee; Teresa R de Candia; Arden Moscati; Dawn L Thiselton; Brion S Maher; Brandon K Wormley; Dermot Walsh; Francis A O'Neill; Kenneth S Kendler; Brien P Riley; Ayman H Fanous
Journal:  Schizophr Bull       Date:  2015-08-27       Impact factor: 9.306

2.  Increased SNARE Protein-Protein Interactions in Orbitofrontal and Anterior Cingulate Cortices in Schizophrenia.

Authors:  Alfredo Ramos-Miguel; Clare L Beasley; Andrew J Dwork; J John Mann; Gorazd Rosoklija; Alasdair M Barr; William G Honer
Journal:  Biol Psychiatry       Date:  2014-12-19       Impact factor: 13.382

3.  Reduced SNAP25 Protein Fragmentation Contributes to SNARE Complex Dysregulation in Schizophrenia Postmortem Brain.

Authors:  Alfredo Ramos-Miguel; Kristina Gicas; Jehan Alamri; Clare L Beasley; Andrew J Dwork; J John Mann; Gorazd Rosoklija; Fang Cai; Weihong Song; Alasdair M Barr; William G Honer
Journal:  Neuroscience       Date:  2018-12-21       Impact factor: 3.590

4.  Synaptosome-Associated Protein 25 (SNAP25) Gene Association Analysis Revealed Risk Variants for ASD, in Iranian Population.

Authors:  Mohammad Reza Safari; Mir Davood Omrani; Rezvan Noroozi; Arezou Sayad; Shaghayegh Sarrafzadeh; Alireza Komaki; Fateme Asadzadeh Manjili; Mehrdokht Mazdeh; Ali Ghaleiha; Mohammad Taheri
Journal:  J Mol Neurosci       Date:  2016-11-26       Impact factor: 3.444

Review 5.  SNARE complex in developmental psychiatry: neurotransmitter exocytosis and beyond.

Authors:  Renata Basso Cupertino; Djenifer B Kappel; Cibele Edom Bandeira; Jaqueline Bohrer Schuch; Bruna Santos da Silva; Diana Müller; Claiton Henrique Dotto Bau; Nina Roth Mota
Journal:  J Neural Transm (Vienna)       Date:  2016-02-08       Impact factor: 3.575

Review 6.  Dysregulations of Synaptic Vesicle Trafficking in Schizophrenia.

Authors:  Chijioke N Egbujo; Duncan Sinclair; Chang-Gyu Hahn
Journal:  Curr Psychiatry Rep       Date:  2016-08       Impact factor: 5.285

Review 7.  New insights into behaviour using mouse ENU mutagenesis.

Authors:  Peter L Oliver; Kay E Davies
Journal:  Hum Mol Genet       Date:  2012-08-13       Impact factor: 6.150

8.  Disrupted circadian rhythms in a mouse model of schizophrenia.

Authors:  Peter L Oliver; Melanie V Sobczyk; Elizabeth S Maywood; Benjamin Edwards; Sheena Lee; Achilleas Livieratos; Henrik Oster; Rachel Butler; Sofia I H Godinho; Katharina Wulff; Stuart N Peirson; Simon P Fisher; Johanna E Chesham; Janice W Smith; Michael H Hastings; Kay E Davies; Russell G Foster
Journal:  Curr Biol       Date:  2012-01-19       Impact factor: 10.834

9.  Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

Authors:  M Ayalew; H Le-Niculescu; D F Levey; N Jain; B Changala; S D Patel; E Winiger; A Breier; A Shekhar; R Amdur; D Koller; J I Nurnberger; A Corvin; M Geyer; M T Tsuang; D Salomon; N J Schork; A H Fanous; M C O'Donovan; A B Niculescu
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

Review 10.  Phenotype ontologies and cross-species analysis for translational research.

Authors:  Peter N Robinson; Caleb Webber
Journal:  PLoS Genet       Date:  2014-04-03       Impact factor: 5.917

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.